Diagnostic Utility of the PD-L1 Immunostaining in Biopsy Specimens of Patients with Biliary Tract Neoplasms

BACKGROUND: Anti-programmed death 1/programmed death ligand 1 (PD1/PD-L1) antibodies have been successfully used as treatment agents for several solid tumors; however, it is difficult to predict their effectiveness. We evaluated whether biopsy specimens could predict the positive status of PD-L1 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Kazuyuki, Ohara, Toshiaki, Fujisawa, Masayoshi, Takaki, Akinobu, Takahara, Masahiro, Kato, Hironari, Yoshida, Ryuichi, Umeda, Yuzo, Yagi, Takahito, Matsukawa, Akihiro, Okada, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184404/
https://www.ncbi.nlm.nih.gov/pubmed/35137343
http://dx.doi.org/10.1007/s11605-021-05197-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184404/
https://www.ncbi.nlm.nih.gov/pubmed/35137343
http://dx.doi.org/10.1007/s11605-021-05197-6

Ejemplares similares